Cancer Immunotherapy

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 3, 2010, Pages 507-518

  Bergman, Philip J ^a,b  

^a BrightHeart Veterinary Centers   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Immunotherapy; Tumor; Vaccine

Indexed keywords

BCG VACCINE; BIOLOGICAL RESPONSE MODIFIER; CANCER GROWTH FACTOR; CANCER VACCINE; CD4 ANTIGEN; CHORIONIC GONADOTROPIN; CORYNEBACTERIUM PARVUM EXTRACT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOPHENOL MONOOXYGENASE; ONCOLYTIC VIRUS; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 5; VINBLASTINE;

ADAPTIVE IMMUNITY; ADENOVIRUS; ANIMAL VENEREAL TUMOR; B LYMPHOCYTE; BLADDER CARCINOMA; BOWEN DISEASE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANINE DISTEMPER MORBILLIVIRUS; CAT; CYTOKINE PRODUCTION; DISEASE MODEL; DOG; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MASTOCYTOMA; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PHAGOCYTE; PROSTATE CARCINOMA; REVIEW; SARCOIDOSIS; SPECIES DIFFERENCE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; VETERINARY MEDICINE;

ANIMALS; CANCER VACCINES; CAT DISEASES; CATS; DOG DISEASES; DOGS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS;

CANIS FAMILIARIS; MURINAE;

EID: 77952764966     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.01.002     Document Type: Review

References (96)

1. Bergman P.J. Biologic response modification. Veterinary oncology secrets 2001, 79-82. Hanley & Belfus, Inc, Philadelphia. 1st edition. R.C. Rosenthal (Ed.).
2. Baxevanis C.N., Perez S.A., Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009, 46:167-189.
3. Reilly R.T., Emens L.A., Jaffee E.M. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?. Curr Opin Investig Drugs 2001, 2(1):133-135.
4. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2(4):293-299.
5. Wallace M.E., Smyth M.J. The role of natural killer cells in tumor control-effectors and regulators of adaptive immunity. Springer Semin Immunopathol 2005, 27(1):49-64.
6. Itoh H., Horiuchi Y., Nagasaki T., et al. Evaluation of immunological status in tumor-bearing dogs. Vet Immunol Immunopathol 2009, 132(2-4):85-90.
7. Schmiedt C.W., Grimes J.A., Holzman G., et al. Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression. Vet Comp Oncol 2009, 7:45-53.
8. Catchpole B., Gould S.M., Kellett-Gregory L.M., et al. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma. J Small Anim Pract 2002, 43(10):464-467.
9. Zagury D., Gallo R.C. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today 2004, 9(2):72-81.
10. Morse M.A., Mosca P.J., Clay T.M., et al. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther 2002, 2(1):35-43.
11. Yamaguchi T., Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006, 16(2):115-123.
12. Richardson M.A., Ramirez T., Russell N.C., et al. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med 1999, 5(3):42-47.
13. Herr H.W., Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008, 179:53-56.
14. Owen L.N., Bostock D.E. Proceedings: tumour therapy in dogs using B.C.G. Br J Cancer 1974, 29:95.
15. MacEwen E.G. An immunologic approach to the treatment of cancer. Vet Clin North Am 1977, 7:65-75.
16. Theilen G.H., Hills D. Comparative aspects of cancer immunotherapy: immunologic methods used for treatment of spontaneous cancer in animals. J Am Vet Med Assoc 1982, 181:1134-1141.
17. MacEwen E.G. Approaches to cancer therapy using biological response modifiers. Vet Clin North Am Small Anim Pract 1985, 15:667-688.
18. Klein W.R., Rutten V.P., Steerenberg P.A., et al. The present status of BCG treatment in the veterinary practice. In Vivo 1991, 5:605-608.
19. Henry C.J., Downing S., Rosenthal R.C., et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res 2007, 68:1246-1251.
20. Parodi A.L., Misdorp W., Mialot J.P., et al. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother 1983, 15:172-177.
21. MacEwen E.G., Patnaik A.K., Harvey H.J., et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 1986, 4(5):397-402.
22. Thamm D.H., Kurzman I.D., King I., et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005, 11:4827-4834.
23. Dow S.W., Elmslie R.E., Willson A.P., et al. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998, 101:2406-2414.
24. Kleinerman E.S., Jia S.-F., Griffin J., et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 1992, 10:1310-1316.
25. MacEwen E.G., Kurzman I.D., Vail D.M., et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999, 5:4249-4258.
26. Teske E., Rutteman G.R., vd Ingh T.S., et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Anticancer Res 1998, 18:1015-1019.
27. Kurzman I.D., MacEwen E.G., Rosenthal R.C., et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995, 1:1595-1601.
28. Vail D.M., MacEwen E.G., Kurzman I.D., et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995, 1:1165-1170.
29. Arendt M., Nasir L., Morgan I.M. Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks. Vet Comp Oncol 2009, 7:153-161.
30. Smith B.F., Curiel D.T., Ternovoi V.V., et al. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother Radiopharm 2006, 21:601-606.
31. Le L.P., Rivera A.A., Glasgow J.N., et al. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther 2006, 13:389-399.
32. Hemminki A., Kanerva A., Kremer E.J., et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003, 7:163-173.
33. Suter S.E., Chein M.B., von M.V., et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res 2005, 11:1579-1587.
34. Meyer T., Stockfleth E. Clinical investigations of toll-like receptor agonists. Expert Opin Investig Drugs 2008, 17:1051-1065.
35. Gill V.L., Bergman P.J., Baer K.E., et al. Use of imiquimod 5% cream (Aldara) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005). Vet Comp Oncol 2008, 6:55-64.
36. Peters-Kennedy J., Scott D.W., Miller W.H. Apparent clinical resolution of pinnal actinic keratoses and squamous cell carcinoma in a cat using topical imiquimod 5% cream. J Feline Med Surg 2008, 10(6):593-599.
37. Tateyama S., Priosoeryanto B.P., Yamaguchi R., et al. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumors. Res Vet Sci 1995, 59:275-277.
38. Kruth S.A. Biological response modifiers: interferons, interleukins, recombinant products, liposomal products. Vet Clin North Am Small Anim Pract 1998, 28:269-295.
39. Whitley E.M., Bird A.C., Zucker K.E., et al. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res 1995, 15:923-929.
40. Hampel V., Schwarz B., Kempf C., et al. Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega. J Vet Intern Med 2007, 21:1340-1346.
41. Finocchiaro L.M., Glikin G.C. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther 2008, 15:267-276.
42. Cutrera J., Torrero M., Shiomitsu K., et al. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008, 423:319-325.
43. Finocchiaro L.M., Fiszman G.L., Karara A.L., et al. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 2008, 15:165-172.
44. Akhtar N., Padilla M.L., Dickerson E.B., et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004, 6:106-116.
45. Dickerson E.B., Fosmire S., Padilla M.L., et al. Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer. J Immunother 2002, 25:36-45.
46. Okano F., Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res 2000, 20:3411-3415.
47. Jahnke A., Hirschberger J., Fischer C., et al. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med 2007, 54:599-606.
48. Dickerson E.B., Akhtar N., Steinberg H., et al. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2004, 2:663-673.
49. Dow S., Elmslie R., Kurzman I., et al. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 2005, 16:937-946.
50. Skubitz K.M., Anderson P.M. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000, 11:555-563.
51. Khanna C., Anderson P.M., Hasz D.E., et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997, 79:1409-1421.
52. Khanna C., Hasz D.E., Klausner J.S., et al. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996, 2:721-734.
53. Jourdier T.M., Moste C., Bonnet M.C., et al. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 2003, 10(26):2126-2132.
54. Siddiqui F., Li C.Y., Zhang X., et al. Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy. Int J Hyperthermia 2006, 22:117-134.
55. Quintin-Colonna F., Devauchelle P., Fradelizi D., et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 1996, 3(12):1104-1112.
56. Kamstock D., Guth A., Elmslie R., et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2006, 13:306-317.
57. Junco J.A., Basalto R., Fuentes F., et al. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med Biol 2008, 617:581-587.
58. Chou P.C., Chuang T.F., Jan T.R., et al. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles. Vet Immunol Immunopathol 2009, 130(1-2):25-34.
59. Chuang T.F., Lee S.C., Liao K.W., et al. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009, 125(3):698-707.
60. Bergman P.J. Anticancer vaccines. Vet Clin North Am Small Anim Pract 2007, 37:1111-1119.
61. Hogge G.S., Burkholder J.K., Culp J., et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 1999, 6(1):26-36.
62. Alexander A.N., Huelsmeyer M.K., Mitzey A., et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006, 55(4):433-442.
63. U'Ren L.W., Biller B.J., Elmslie R.E., et al. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 2007, 21:113-120.
64. Bird R.C., Deinnocentes P., Lenz S., et al. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol 2008, 123:289-304.
65. Turek M.M., Thamm D.H., Mitzey A., et al. Human granulocyte & macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. Vet Comp Oncol 2007, 5:219-231.
66. Kuntsi-Vaattovaara H., Verstraete F.J.M., Newsome J.T., et al. Resolution of persistent oral papillomatosis in a dog after treatment with a recombinant canine oral papillomavirus vaccine. Vet Comp Oncol 2003, 1:57-63.
67. Milner R.J., Salute M., Crawford C., et al. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet Immunol Immunopathol 2006, 114:273-284.
68. Kamstock D., Elmslie R., Thamm D., et al. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007, 56:1299-1309.
69. von E.H., Sadeghi A., Carlsson B., et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 2008, 31:377-384.
70. Johnston K.B., Monteiro J.M., Schultz L.D., et al. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes. Virology 2005, 336:208-218.
71. Thacker E.E., Nakayama M., Smith B.F., et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009, 27(50):7116-7124.
72. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 2005, 19(1):56-63.
73. Tamura K., Arai H., Ueno E., et al. Comparison of dendritic cell-mediated immune responses among canine malignant cells. J Vet Med Sci 2007, 69:925-930.
74. Tamura K., Yamada M., Isotani M., et al. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. Vet J 2008, 175:126-129.
75. Rodriguez-Lecompte J.C., Kruth S., Gyorffy S., et al. Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity?. Anim Health Res Rev 2004, 5:227-234.
76. Kyte J.A., Mu L., Aamdal S., et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006, 13:905-918.
77. Mason N.J., Coughlin C.M., Overley B., et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 2008, 15:955-965.
78. Jeglum K.A. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Vet Clin North Am Small Anim Pract 1996, 26(1):73-85.
79. Bergman P.J., Camps-Palau M.A., McKnight J.A., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24(21):4582-4585.
80. Bergman P.J., McKnight J., Novosad A., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003, 9(4):1284-1290.
81. Liao J.C., Gregor P., Wolchok J.D., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006, 6:8.
82. Goubier A., Fuhrmann L., Forest L., et al. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNgamma T cell responses in the dog. Vaccine 2008, 26:2186-2190.
83. Bergman P.J., Wolchok J.D. Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma. Cancer Ther 2008, 6:817-826.
84. Wolchok J.D., Yuan J., Houghton A.N., et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007, 15:2044-2050.
85. Perales M.A., Yuan J., Powel S., et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 2008, 16:2022-2029.
86. Yuan J., Ku G.Y., Gallardo H.F., et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009, 9:5.
87. Peggs K.S., Quezada S.A., Korman A.J., et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18(2):206-213.
88. Graves S.S., Stone D., Loretz C., et al. Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig. Transplantation 2009, 88:317-322.
89. Biller B.J., Elmslie R.E., Burnett R.C., et al. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 2007, 116:69-78.
90. Horiuchi Y., Tominaga M., Ichikawa M., et al. Increase of regulatory T cells in the peripheral blood of dogs with metastatic tumors. Microbiol Immunol 2009, 53:468-474.
91. O'Neill K., Guth A., Biller B., et al. Changes in regulatory T cells in dogs with cancer and associations with tumor type. J Vet Intern Med 2009, 23:875-881.
92. Thamm D.H. Interactions between radiation therapy and immunotherapy: the best of two worlds?. Vet Comp Oncol 2006, 4:189-197.
93. Walter C.U., Biller B.J., Lana S.E., et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 2006, 20(2):342-347.
94. Emens L.A., Jaffee E.M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005, 65(18):8059-8064.
95. Khanna C., London C., Vail D., et al. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res 2009, 15:5671-5677.
96. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8:147-156.